Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc. Beats on EPS, Stock Up 6.38%

Corvus Pharmaceuticals reported a narrower-than-expected loss per share, which led to a positive stock reaction, with shares rising 6.38%. However, there was no revenue reported, and no guidance was provided for future performance. Investors may view the EPS beat as a sign of improved cost management or operational efficiency.